Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma (SPL) has found its antiviral VIRALEZE candidate is well tolerated and is not absorbed into the bloodstream during a recent clinical safety study
- Forty volunteers used the product four times a day for 14 days as part of the randomised, double-blind, placebo-controlled study
- Starpharma says the product “was well tolerated with no notable or serious adverse events reported”
- Starpharma shares are trading 2.31 per cent higher at $1.33
Starpharma (SPL) has found its antiviral VIRALEZE candidate is “very well tolerated” and is not absorbed into the bloodstream during a recent clinical safety study.
The study sought to confirm the product was safe and well-tolerated when used on healthy volunteers and confirm that the dendrimer antiviral in VIRALEZE, SPL7013 was not absorbed into the bloodstream following nasal application.
Forty volunteers used the product four times a day for 14 days as part of the randomised, double-blind, placebo-controlled study.
Starpharma said the product “was well tolerated with no notable or serious adverse events reported” and also confirmed SPL7013 was not detected in the bloodstream after repeated nasal application.
Starpharma Chief Executive Officer, Dr Jackie Fairley, said the additional data demonstrated SPL7013’s safety profile.
“We are pleased to report that VIRALEZE was very well tolerated in the study,” she said.
“These data further support the suitability of VIRALEZE antiviral nasal spray for use in everyday situations as a preventative product where individuals may be at risk of exposure to respiratory viruses.”
Starpharma shares were trading 2.31 per cent higher at $1.33 at 1:28 pm AEST.
